

ISO 20399:2022-12 (E)

Biotechnology - Ancillary materials present during the production of cellular therapeutic products and gene therapy products

Contents		Page
Foreword		v
Introduction		vi
1	Scope	1
2	Normative references	1
3	Terms and definitions	1
4	Abbreviated terms	4
5	Strategy	5
5.1	Key concepts on AM	5
5.2	AM-related responsibilities	5
5.3	Qualification considerations of AM	6
5.4	Animal-derived components of AM	7
5.4.1	General	7
5.4.2	Key considerations in the use of animal-derived components	7
5.4.3	Viral inactivation	8
6	Evaluation criteria and risk mitigation for AM containing biological material	8
6.1	Evaluation criteria for AM selection	8
6.2	Mitigation of risk	10
6.2.1	Scientific approach	10
6.2.2	Supplier audit and questionnaires	11
6.2.3	Risk assessment	12
7	AM characteristics and quality attributes	12
7.1	AM components, identity and purity	12
7.1.1	General	12
7.1.2	Identity and quantity of component(s)	13
7.1.3	Purity and impurity	13
7.1.4	Lot-to-lot consistency for AMs containing proprietary components	13
7.2	AM storage and stability	14
7.2.1	General	14
7.2.2	Stability and storage conditions	14
8	AM manufacturing and biosafety	15
8.1	Quality management system	15
8.2	Manufacturing process	16
8.3	Container and closure systems	16
8.4	Animal and human-derived components	16
8.5	Safety to cells and humans	17
9	AM performance	17
9.1	General	17
9.2	Quality and testing	18
9.3	Qualification activity	18
9.4	Performance assay	19
9.5	Performance assay results	19

10	AM documentation	19
10.1	General	19
10.2	Reporting requirements	20
10.3	Certificate of analysis	21
10.4	Additional certificates	22
10.4.1	Certificate of origin	22
10.4.2	Certificate of compliance	22
10.4.3	Certificate of irradiation	22
11	Managing changes to components	22
11.1	Impact of changes to components	22
11.2	Measures for managing changes to components	22
	Annex A (informative) Decision chart of AMs	24
	Annex B (informative) Example workflow from AM supplier to AM user	26
	Annex C (informative) Information on AM and materials used to produce AMs	27
	Annex D (informative) Considerations for the characterization of AMs	29
	Annex E (informative) Quality declarations for manufactured biological materials used in the manufacture of a cell-based therapeutic product	30
	Bibliography	31